Mass Tort - Construction Site Accidents
- Unsafe Drugs
- Stock Market Losses
- Unsafe Products
- Environmental Toxins
- Personal Injury
- Employment Law
- Medical Malpractice
- Class Action
Practice Area Attorneys
Bextra®
Contact us today for a free legal consultation about your Bextra® case.
Bextra® is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (“NSAID”) used to relieve the symptoms of osteoarthritis and rheumatoid arthritis in adults and painful menstrual cycles.
Bextra was approved for use in the United States in November 2001. In preliminary results, Bextra® was found to increase the incidence of heart attacks and strokes by 2.19 times. It is alleged that at the time of approval, the FDA were aware of some serious skin-related side effects that could occur from using the drug. Nevertheless, approval was given, and the drug was welcomed by physicians and patients throughout the country.
On April 7, 2005, the FDA requested that Pfizer suspend sales of Bextra® in the United States. The FDA based its decision, in part, on the increased risk of cardiovascular events such as heart attacks and strokes alongside reports of serious and potentially life-threatening skin reactions such as Stevens Johnsons Syndrome and toxic epidermal necrolysis.
If you have taken Bextra® and have been adversely affected, one of our Philadelphia Bextra® injury attorneys can assist you in evaluating your case. Click here to contact us for a free case evaluation.